

Company name: Minapharm pharmaceutical

an audited financial indicator for the financial year period ended on 31/03/2024.

Currency: EGP

(The form should include the company's comment on the results of the business with the most important factors that led to profit/loss)

First, the financial indicators

(A) statement of profit or loss for the year/period ended on 30/06/2024.

	Current period	comparative financial statements	change%
Revenue/sales	1,313,387,762	1,251,100,448	9%
Total profit (loss)	336,204,918	416,118,978	-12%
The ratio of total profit to revenue/sales	0.26	0.33	-22%
Net profit (loss) before tax from continuing activities	-122,085,836	105,697,127	-97%
Net profit (loss) before tax from non-continuing activities (if any)	-	-	0%
Net profit (loss) after tax	-121,794,135	77,484,708	-98%
Earnings / (losses) per share (EPS)	-12.04	5.98	-100%
Diluted share of profit / loss (if any)	-	-	0%

شركة مينافارم للأدوية والصناعات الكيماوية
ط ٢ ش. البرديس من أسماء فهمى
خلف الرقابة الإدارية - أرض الجولف

Head Office: 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt
Factory: 10th of Ramadan City - Egypt

(B) Statement of financial position in 30/06/2024.

	Current period	comparative financial year (previous Year)	change%
Net working capital	1,174,777,891-	602,862,917-	26%
Owner's equity	1,014,829,021	1,179,461,705	0.06%
Paid capital	122,934,400	122,934,400	0%
Reserves	291,996,136	291,996,136	0%
Retained earnings	791,319,155	627,652,811	33%
The profit (loss) of the period	121,794,135-	206,504,893	-99.67%
Other			
Treasury Shares	69,626,535	69,626,535	0%

(C) cash flow statement for the year 30/06/2024

	Current period	comparative financial statements	Change%
Cash flows from (to) operating activities	31,172,143	244,347,034	-138%
Cash flows from (to) investment activities	336,908,378-	736,111,431-	-73%
Cash flows from (to) financing activities	644,749,889	710,548,536	10%

Second: Material events that have occurred since the date of the financial results till now and should be disclosed.

None

(If any, please mention it in Annex (1))

شركة مينافارم للأدوية والصناعات الكيماوية
٢ ط ش. البرديس من أسماء فهمى
خلف الرقابة الإدارية - أرض الجولف

Agree

We acknowledge that the above-mentioned statements are extracted from the Company's financial statements issued by the Board of Directors held on 13 /08 / 2024 and have not yet issued the auditor's report and we undertake to promptly disclose to FRA and EGX if any change in these statements as soon as it occurs until the submission of the signed financial statements which we undertake to send immediately after Issue the auditor/auditor's report before the beginning of the trading session of the following day according to the date recorded in the auditor's report, which we expect to be a " clean" report .


(if amended, please state the reasons given in the annex (No. 2)).

Investor relations officer

Date 13 / 08 / 2024



Chairman



The company's stamp.

شركة مينافارم للأدوية والصناعات الكيماوية
٢ ط ش. البرديس من أسماء فهمى
خلف الرقابة الإدارية - أرض الجولف

Head Office: 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt
Factory: 10th of Ramadan City - Egypt